Quetiapine Treatment for Symptoms Associated With Borderline Personality Disorder
Status:
Completed
Trial end date:
2008-05-01
Target enrollment:
Participant gender:
Summary
Objective:
The objective of this study is to quantitatively examine the efficacy of Seroquel (active
ingredient quetiapine fumarate) in subjects with Borderline Personality Disorder (BPD). A
secondary objective is to characterize the safety and tolerability of utilizing quetiapine in
patients with Borderline Personality Disorder.
Design:
Investigator initiated, 6-week, non-placebo controlled, non-randomized, open-label, single
drug, single-center, medication trial.
Participants:
Volunteers (n = 15) diagnosed with Borderline Personality Disorder using the Structured
Clinical Interview for DSM-IV Personality Disorders (SCID-II).
Interventions:
Subjects with Borderline Personality Disorder are washed out of all other medications. The
subjects are then given the study drug at a dose within the drug's known therapeutic range.
Phase:
Phase 3
Details
Lead Sponsor:
University of Medicine and Dentistry of New Jersey